NASDAQ:COYA Coya Therapeutics (COYA) Stock Price, News & Analysis $4.25 -0.09 (-2.07%) Closing price 04:00 PM EasternExtended Trading$4.26 +0.01 (+0.35%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Coya Therapeutics Stock (NASDAQ:COYA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Coya Therapeutics alerts:Sign Up Key Stats Today's Range$4.16▼$4.3950-Day Range$4.18▼$5.3052-Week Range$3.71▼$7.55Volume134,191 shsAverage Volume156,997 shsMarket Capitalization$99.71 millionP/E RatioN/ADividend YieldN/APrice Target$15.33Consensus RatingModerate Buy Company Overview Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that regulate neuroinflammation and support immune-system function. The company’s research centers on regulatory T cells, or Tregs, immune cells that help control excessive inflammatory responses. Coya is developing treatments intended for neurodegenerative diseases in which inflammation may contribute to disease progression. The company’s lead programs include COYA 101, an autologous Treg cell therapy in which a patient’s cells are collected, expanded and activated outside the body, and then administered as a potential treatment for amyotrophic lateral sclerosis (ALS). Coya is also developing combination approaches, including COYA 302, which is designed to combine Treg-based therapy with immune-modulating treatment. The company’s broader pipeline is intended to address additional neurodegenerative and inflammatory conditions. Coya Therapeutics is headquartered in Houston, Texas, and conducts its development activities through clinical research and collaborations with academic and medical institutions. Its programs remain investigational and are subject to clinical testing and regulatory review.AI Generated. May Contain Errors. Read More Coya Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreCOYA MarketRank™: 2.315501757125 of 5 starsCoya Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 618th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCoya Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCoya Therapeutics has a consensus price target of $15.33, representing about 260.8% upside from its current price of $4.25.Amount of Analyst CoverageCoya Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Coya Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Coya Therapeutics are expected to decrease in the coming year, from ($1.34) to ($1.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coya Therapeutics is -3.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coya Therapeutics is -3.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoya Therapeutics has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Coya Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.41% of the float of Coya Therapeutics has been sold short.Short Interest Ratio / Days to CoverCoya Therapeutics has a short interest ratio ("days to cover") of 7.02.Change versus previous monthShort interest in Coya Therapeutics has recently increased by 0.30%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCoya Therapeutics does not currently pay a dividend.Dividend GrowthCoya Therapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.40 News SentimentCoya Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Coya Therapeutics this week, compared to 3 articles on an average week.MarketBeat Follows4 people have added Coya Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Coya Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.10% of the stock of Coya Therapeutics is held by insiders.Percentage Held by Institutions39.75% of the stock of Coya Therapeutics is held by institutions.Read more about Coya Therapeutics' insider trading history. Receive COYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COYA Stock News HeadlinesCoya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALSOctober 14 at 1:44 PM | marketscreener.comMCoya Therapeutics, Inc. Plans to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALSOctober 14 at 1:44 PM | marketscreener.comMSpaceX minted 4400 millionaires in a single daySpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into millionaires. One welder's $10,000 stock package made him a millionaire on IPO day. Former Wall Street CEO Dylan Jovine says Elon Musk's next venture could outsize everything he's built before. It runs on an obscure AI firm Musk has relied on since 2012, supplying crucial technology to Tesla, Starlink and SpaceX.October 16 at 1:00 AM | Behind the Markets (Ad)Coya launches open-label ALS extension, reprioritizes pipelineOctober 14 at 9:11 AM | tipranks.comCoya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare ConferenceOctober 13 at 8:59 AM | finance.yahoo.comCoya Therapeutics, Inc. Completes Full Enrollment In Phase 2/3 ALSTARS Trial Of COYA 302 For The Treatment Of ALSOctober 6, 2026 | marketscreener.comMCoya Gains on Test NewsOctober 5, 2026 | baystreet.caCoya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALSOctober 5, 2026 | finance.yahoo.comSee More Headlines COYA Stock Analysis - Frequently Asked Questions How have COYA shares performed this year? Coya Therapeutics' stock was trading at $5.80 at the start of the year. Since then, COYA shares have decreased by 26.7% and is now trading at $4.25. How were Coya Therapeutics' earnings last quarter? Coya Therapeutics, Inc. (NASDAQ:COYA) released its earnings results on Tuesday, August, 11th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.07. The firm earned $0.24 million during the quarter, compared to analyst estimates of $0.13 million. Coya Therapeutics had a negative net margin of 270.22% and a negative trailing twelve-month return on equity of 52.05%. When did Coya Therapeutics IPO? Coya Therapeutics (COYA) raised $15 million in an initial public offering on Thursday, December 29th 2022. The company issued 3,050,000 shares at a price of $5.00 per share. How do I buy shares of Coya Therapeutics? Shares of COYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Coya Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Coya Therapeutics investors own include NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), Snowflake (SNOW), Bristol Myers Squibb (BMY), Enterprise Products Partners (EPD), IonQ (IONQ) and Merck & Co., Inc. (MRK). Company Calendar Last Earnings8/11/2026Today10/16/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 COYA's financial health is in the Green zone, according to TradeSmith. COYA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:COYA CIK1835022 Webwww.coyatherapeutics.com Phone(650) 739-3939FaxN/AEmployees8Year Founded2016Price Target and Rating Average Price Target for Coya Therapeutics$15.33 High Price Target$18.00 Low Price Target$12.00 Potential Upside/Downside+260.8%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.23 million Net Margins-270.22% Pretax Margin-270.18% Return on Equity-52.05% Return on Assets-46.34% Debt Debt-to-Equity RatioN/A Current Ratio13.40 Quick Ratio13.40 Sales & Book Value Annual Sales$7.95 million Price / Sales12.54 Cash FlowN/A Price / Cash FlowN/A Book Value$2.06 per share Price / Book2.06Miscellaneous Outstanding Shares23,460,000Free Float22,027,000Market Cap$99.71 million OptionableNot Optionable Beta0.58 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:COYA) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredSpaceX minted 4400 millionaires in a single daySpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
